Steroid plus anti-VEGF vs. anti-VEGF alone for diabetic macular edema
Part of Cancer, Immune system & allergy clinical trials.
This trial tests if combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than aflibercept alone for people with diabetic macular edema caused by inflammation. It aims to find the best first treatment for improving vision and reducing swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with type 1 or type 2 diabetes.
- Your blood sugar needs to be well-controlled, with a recent HbA1c score of 10% or lower.
- You have diabetic retinopathy stages II to IV and center-involved macular edema with a retinal thickness of at least 300 microns.
- Your vision in the study eye is worse than 20/25 (but better than 20/400).
- You have at least one sign of inflammatory swelling on an OCT scan, such as large cysts, fluid under the retina, or hard deposits.
- You must not have had any prior treatment for diabetic macular edema in the study eye, including anti-VEGF shots or steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This trial tests a higher dose of aflibercept (8 mg) for people whose diabetic macular edema, retinal vein occlusion, or myopic choroidal neovascularization has not improved with standard treatment. The goal is to see if this stronger dose can reduce fluid and improve vision.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.